Status:

COMPLETED

An Evaluation of the Causes of Anemia in Patients With Heart Failure

Lead Sponsor:

Montreal Heart Institute

Collaborating Sponsors:

Johnson & Johnson

Conditions:

Anemia

Heart Failure

Eligibility:

All Genders

18+ years

Brief Summary

Anemia is frequent in patients with heart failure. Few studies have clearly addressed the causes of anemia in patients with HF. The purpose of this study is to evaluate differences in blood concentrat...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Groups 1 and 2
  • Age \>18 years
  • Group 1: hemoglobin \< 120g/L in women and \< 130 g/L in men (in agreement with the WHO definition of anemia)
  • Group 2: hemoglobin \> or = 120g/L in women and \> or = 130 g/L in men
  • Patients with chronic HF referred to a specialized HF clinic, or with a diagnosis of HF at least 6 months prior to enrolment
  • NYHA functional class II-IV at the time of enrolment
  • Patients already on CHF medical therapy (ACEI or ARBs, beta-blockers if tolerated, with or without digoxin, and loop diuretics), at stable doses for \> or = 1 month
  • LVEF \< or = 40% within 6 months prior to patient enrolment, by echocardiography, radionuclide ventriculography or perfusion scan, or radiologic angiography
  • Inclusion criteria - group 3
  • Age \>18 years
  • At least moderate CRF (eGFR \< 60ml/min/1,73m2)
  • With or without anemia
  • LVEF \> or = 50% within 6 months prior to patient enrolment, by echocardiography, radionuclide ventriculography or perfusion scan, or radiologic angiography
  • Exclusion Criteria (all groups):
  • Recent acute renal failure episode (\< 1 month)
  • Red blood cells (or other blood component) transfusions or EPO therapy within 3 months prior to enrolment
  • Iron, B12 or folic acid supplements used to treat anemia (\< 3 months)
  • Evidence of active GI bleeding
  • Recent acute coronary syndrome or decompensated HF episode (\< 1 month)
  • Complex congenital heart disease
  • Known malignant hematologic or other active neoplasia
  • Immunosuppressive therapy, chemotherapy or radiotherapy within 3 months prior to enrolment
  • Recent acute decompensation of a chronic inflammatory disease (e.g. chronic inflammatory bowel disease, rheumatoid arthritis, collagen vascular disease) within 3 months prior to enrolment
  • Recent viral or bacterial syndrome (\< 2 weeks)
  • Active or recent viral hepatitis (\< 3 months)
  • Pregnant women
  • Potential for non compliance to tests involved in this protocol
  • Incapacity to provide informed consent

Exclusion

    Key Trial Info

    Start Date :

    January 1 2008

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    180 Patients enrolled

    Trial Details

    Trial ID

    NCT00834691

    Start Date

    January 1 2008

    Last Update

    August 2 2010

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Montreal Heart Institute

    Montreal, Quebec, Canada, H1T 1C8